Serous Otitis Media (Otitis Media With Effusion)

Definition

• Shambaugh Surgery of the Ear, p. 451
• Tintinalli's Emergency Medicine, p. 144

Epidemiology

• Point prevalence in children: up to 20% on screening tests
• More than 2 million episodes are diagnosed annually in the United States, with an estimated annual cost of $4 billion
• Peak incidence: 6 months to 4 years of age
• By age 3 years, nearly all children have experienced at least one OME episode
• 90% of children will be affected before school age
• Cummings Otolaryngology, p. 3767
• Tintinalli's Emergency Medicine, p. 144

Risk Factors

• Onset of first AOM before 12 months of age
• Male sex
• Genetic predisposition
• Craniofacial abnormalities (cleft palate)
• Immunodeficiency
• Adenoid hypertrophy
• Down syndrome and other craniofacial syndromes

• Low socioeconomic status
• Recurrent upper respiratory tract infections
• Daycare attendance
• Tobacco smoke exposure
• Pacifier use
• Fall/winter season

• Cummings Otolaryngology, p. 3767

Pathophysiology

Eustachian Tube Dysfunction

• Shorter and more horizontal than in adults
• More flexible and more easily obstructed

1. Inflammatory causes - mucosal edema from allergic disease, laryngopharyngeal/gastroesophageal reflux, ciliary dysmotility
2. Anatomic obstruction - prominent adenoid tissue, synechiae, nasopharyngeal masses
3. Congenital anomalies - cleft palate, palatal myopathies

Biofilm Hypothesis

• Biofilm-aggregated bacteria (primarily H. influenzae) are sequestered on the mucosal surface rather than free-floating in the fluid, explaining why standard cultures are negative
• Hall-Stoodley (2006) found biofilms in 92% of pediatric OME patients by confocal laser-scanning microscopy
• Bacterial toxins initiate a cascade of pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, IL-8 and immunoregulatory cytokines IL-2, IL-4, IL-5, IL-10, IFN-γ
• TNF-α and IL-1β are the primary drivers of middle ear and mastoid inflammation

Effusion Formation

• Proliferation of mucosal lining
• Secretion of mucus by goblet cells
• Differentiation of basal cells into goblet and ciliated cells
• Production of mucins (glycoproteins that determine viscosity) - the primary determinant of effusion type (serous vs. glue-like/mucoid)

• Shambaugh Surgery of the Ear, pp. 450-452

Pathology / Otoscopic Appearance

• An amber-colored or yellowish effusion visible behind an intact tympanic membrane
• Air-fluid levels or bubbles may be seen
• Reduced tympanic membrane mobility on pneumatic otoscopy
• Retracted or dull TM; loss of the light reflex in some cases
• No erythema, no bulging (distinguishing from AOM)

• Atrophy of the tympanic membrane
• Ossicular fixation and erosion may occur

Clinical Features

• Conductive hearing loss - mild to moderate, typically 10-20 dB (can reach 25 dB HL)
• Aural fullness, popping sensation
• Mild intermittent ear pain
• Balance problems and vestibular dysfunction
• Speech, language, and learning difficulties in children with persistent bilateral disease
• Behavioral problems

Diagnosis

• Type B (flat) tympanogram - no compliance peak - indicates middle ear effusion
• Type C - negative pressure with reduced compliance

High-Risk Groups for Developmental Complications

• Permanent hearing loss independent of OME
• Suspected or confirmed speech and language delays
• Autism spectrum disorder
• Down syndrome or craniofacial disorders with cognitive delay
• Cleft palate
• Blindness or uncorrectable visual impairment
• Developmental delay

Management

1. Watchful Waiting (First-Line for Most)

• Most children resolve spontaneously within several months
• For children not at risk for speech/language/learning disabilities: 3 months of observation with monitoring is recommended
• Review at 3-6 month intervals until MEE resolves
• Proceed to intervention if: OME persists >3 months with hearing loss, language/learning delay identified, or structural TM abnormalities develop

2. Medical Treatments

Recent evidence note: A 2025 Cochrane review (PMID 41307300) on decongestants/antihistamines for acute OM in children reinforces that these drugs lack benefit and may cause harm - consistent with current guidelines.

3. Surgical Treatment

• Standard surgical treatment for persistent OME
• Alleviate conductive hearing loss by draining fluid as a proxy for the dysfunctional ET
• Effect on hearing is modest and diminishes after 6-9 months (median tube function duration)
• Indications:
  • Persistent MEE with documented hearing difficulties after 3 months
  • Children at risk for, or already with, speech/language/learning disabilities (Box 199.1)
  • Hearing level ≥25 dB HL in both ears persisting ≥3 months
  • Largest benefit in young children in high-infection environments (e.g., daycare) and older children with bilateral significant hearing loss

• Most beneficial in children aged ≥4 years
• As adjunct to tympanostomy tube insertion: reduces need for reinsertion by ~10%
• Improves ET and middle ear function
• The TARGET study supports adjuvant adenoidectomy in children >3 years undergoing grommet insertion

• Cummings Otolaryngology, pp. 3773-3775
• Tintinalli's Emergency Medicine, p. 144

Complications of Untreated/Persistent OME

• Conductive hearing loss with speech/language delay
• Tympanic membrane atrophy
• Ossicular fixation and erosion
• Balance and vestibular dysfunction
• Retraction pockets - may progress to cholesteatoma
• Adhesive otitis media

Key Differentials

• Cummings Otolaryngology Head and Neck Surgery (Schilder section, pp. 3767-3775)
• Shambaugh Surgery of the Ear (pp. 450-452)
• Tintinalli's Emergency Medicine (pp. 144-148)
• Scott-Brown's Otorhinolaryngology Head & Neck Surgery, Vol. 2

Tympanostomy Tubes (Ventilation Tubes / Grommets)

Overview

• Scott-Brown's Otorhinolaryngology, Vol. 2, p. 169
• Cummings Otolaryngology, p. 3774

Indications

Primary Indications

1. Otitis media with effusion (OME) / Serous otitis media - persistent MEE with hearing difficulties after 3 months of watchful waiting
2. Recurrent acute otitis media (rAOM) - typically ≥3 episodes in 6 months or ≥4 episodes in 12 months
3. Eustachian tube dysfunction - with chronic negative middle ear pressure, TM retraction, or atelectasis

High-risk children warrant earlier/lower threshold insertion:

• Permanent hearing loss independent of OME
• Speech and language delays
• Autism spectrum disorder
• Down syndrome or craniofacial disorders (e.g., cleft palate)
• Blindness or uncorrectable visual impairment
• Developmental delay

Specific thresholds for OME (per guidelines):

• Hearing level ≥25 dB HL in both ears persisting ≥3 months
• Documented hearing difficulties after 3 months with risk factors for developmental delay
• Cummings Otolaryngology, pp. 3773-3774

Types of Tympanostomy Tubes

1. Short-term / Grommet-type (e.g., Shepard, Shah, Armstrong, Donaldson)

• Standard first-line tube for most children
• Flanged design with short barrel
• Extrusion timeline: Up to 55% of Shepard tubes extrude within 6 months; Armstrong tubes ~50% by 12 months, 75% by 18 months
• Lower complication rates compared to long-term tubes

2. Long-term / T-tubes (e.g., Goode T-tube)

• T-shaped flanges on both ends anchor the tube in the TM for longer duration
• ~10% extruded by 6 months (vs. 55% for Shepard)
• Indications for T-tube: atrophic TM, multiple previous sets of grommets, or comorbidities such as cleft palate causing rapid re-accumulation
• Drawbacks: higher rates of persistent perforation (16.6% vs. 2.2% for short-term), plugging, infection, and TM thinning

Tube Materials

• Available in Teflon (PTFE), silicone, titanium, gold- or silver oxide-coated versions
• Titanium/gold/silver oxide coatings aim to reduce biofilm formation; in vitro evidence suggests benefit only if antibiotic-coated
• Ionized processed silicone appears more resistant to biofilm, reducing tube plugging and post-operative otorrhoea
• A recent trial (n=400) comparing tube materials/shapes found silicone tubes were associated with the longest time to first infection; Long Armstrong tubes were least prone to extrude
• Cummings Otolaryngology, pp. 3774-3775
• Scott-Brown's Otorhinolaryngology, Vol. 2, pp. 169-170

Surgical Procedure

Right tympanic membrane with Shah grommet in situ (Scott-Brown's)

Anaesthesia

• Most children: general anaesthesia
• Selected young children: office setting with local anaesthesia (laser-assisted myringotomy is an alternative)

Steps

1. Binocular operating microscope - mandatory
2. Cerumen and debris removal; full TM inspection for abnormalities
3. Myringotomy incision in the anteroinferior quadrant of the pars tensa
   • Radial or circumferential incision (no difference in extrusion rate)
   • Anteroinferior placement lengthens tube survival (80% vs. 45% at 6 months compared to posteroinferior) and reduces perforation risk
   • Never posterosuperior - risk of ossicular chain damage
4. Aspiration of MEE (if present) through the incision
   • If fluid too viscous: counter-incision inferiorly, or saline irrigation to assist aspiration
   • Note: evidence is mixed on whether aspiration actually affects outcomes (some data shows no hearing benefit and possible increased tympanosclerosis from trauma)
5. Tube inserted with alligator forceps
6. Optional: topical antibiotic-steroid drops at time of insertion to reduce early infection (reduces rate from ~9% to ~1%)

• Cummings Otolaryngology, p. 3774
• Scott-Brown's Otorhinolaryngology, Vol. 2, pp. 169-170

Outcomes (Evidence)

Hearing

• At 3 months: +12 dB improvement in the ventilation tube group vs. non-surgical group
• At 12 months: difference becomes almost negligible as tubes extrude and OME naturally resolves in many
• Average hearing benefit over year 1: 5.7 dB
• Average benefit over 2 years: reduced to 3.1 dB
• Note: Even with a functioning tube, an air-bone gap of ~13 dB persists due to effusion and oedema around the ossicular chain

• Grommets beneficial at 6 months (mean 12 dB better at 3 months, ~4 dB better at 6-9 months)
• Effects on hearing diminish in the first year; not maintained at 12 months

Speech, Language, Development, Quality of Life

• Trial evidence is limited but supports beneficial effects on speech, language, behaviour, cognitive function, and quality of life
• Impact is largest in:
  • Young children in high-infection environments (daycare)
  • Older children with bilateral HL ≥25 dB HL persisting ≥3 months
  • Children with developmental risk factors
• Scott-Brown's Otorhinolaryngology, Vol. 2, pp. 170-172

Post-operative Follow-up

• First review: 2-3 months post-surgery (otoscopy, hearing assessment)
• Subsequent: every 6-12 months until tubes extrude and TM is confirmed intact
• Water precautions: swimming/bathing restrictions are traditionally advised, though evidence for their strict necessity is limited

Complications

Early Complications

Otorrhoea - Key Points

• Most common complication: 10-50% incidence
• Causative organisms: Nontypeable H. influenzae, S. aureus, P. aeruginosa (often polymicrobial)
• Risk factors: young age, rAOM as indication, recurrent URTIs, older siblings
• First-line treatment: topical fluoroquinolone (ciprofloxacin/ofloxacin) ear drops
  • Superior to oral antibiotics (failure rate 23% vs. 70% for oral amoxicillin in RCT)
  • Ofloxacin preferred over ciprofloxacin to minimise resistance to a systemically used antibiotic
• Avoid aminoglycoside drops - risk of ototoxicity and vestibulotoxicity
• If no resolution after 2 weeks: culture from tube opening to guide therapy
• If yeast: topical antifungal (clotrimazole)
• Chronic/persistent otorrhoea refractory to treatment: consider tube removal (~4% of cases)

Late Complications

• Cummings Otolaryngology, pp. 3773-3775
• Scott-Brown's Otorhinolaryngology, Vol. 2, pp. 171-173

Persistent Perforation - Management

• Ensure Eustachian tube function has improved
• Opposite ear TM should be intact and infection-free for at least 1 year

• Myringoplasty with fat, surgical gel, paper patch, or reinforced skin closure strips
• Conventional tympanoplasty with fascia or perichondrium graft

Adjuvant Adenoidectomy

• Most beneficial in children ≥4 years (also considered ≥3 years per TARGET study)
• Reduces need for tube reinsertion by approximately 10% vs. tubes alone
• Acts by removing adenoid tissue that obstructs the ET orifice and serves as a bacterial reservoir
• Does not significantly improve hearing outcomes vs. tubes alone in the short term

Contraindications / Cautions

• Cleft palate: higher rates of early extrusion; T-tubes preferred
• Down syndrome: higher threshold for surgery in some guidelines; hearing aids may be first-line (UK) vs. tubes (US)
• Immunocompromise: higher infection risk post-insertion
• Single hearing ear: extra caution - risk of perforation or hearing damage

Recent Evidence Update

• PMID 38666491 (Lam et al., Laryngoscope 2024): Systematic review - quality of life outcomes after pediatric otitis media surgery; confirms benefit
• PMID 40673630 (Clementi et al., Laryngoscope 2025): Systematic review of complications with automated tympanostomy tube systems (iontophoresis-based office procedure) - a growing area

• Cummings Otolaryngology Head and Neck Surgery (pp. 3774-3775)
• Scott-Brown's Otorhinolaryngology Head & Neck Surgery, Vol. 2 (pp. 169-173)
• K.J. Lee's Essential Otolaryngology (p. 217)